Brought to you by 
Immuno-oncology company Neon Therapeutics raises $70mm in Series B financing; later adds $36mm more
07 Dec 2017
Executive Summary
Neon Therapeutics raised $70mm in its Series B financing round led by Partner Fund Management. Returning backers Third Rock Ventures and Access Industries joined new investors Fidelity Management & Research, Wellington Management Company, Inbio Ventures, and Nextech Invest. The company will use the funds toward its lead program NEOPV01, a fully personalized neoantigen vaccine, currently in Phase Ib trials; for preclinical development of NEOPTC01, a personalized adoptive T-cell program; and for the Shared Neoantigen Program. Neon has raised $125mm to date through its A and B rounds.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immuno-oncology company Neon Therapeutics raises $70mm in Series B financing; later adds $36mm more
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice